COLGATE PALMOLIVE CO 8-K

What Happened

• Colgate‑Palmolive announced on March 12, 2026 that its Board elected Christopher S. Boerner, Ph.D., to the Board effective March 15, 2026. Dr. Boerner, 55, is Board Chair and CEO of Bristol‑Myers Squibb (CEO since Nov 2023; Board Chair since Apr 2024) and has extensive leadership experience in the pharmaceutical and healthcare sectors.
• On the same date, director Steven A. Cahillane informed the Board he will not stand for reelection at Colgate‑Palmolive’s Annual Meeting of Stockholders on May 8, 2026, citing the demands of his new role as CEO of The Kraft Heinz Company. The 8‑K was signed by Jennifer M. Daniels, Chief Legal Officer and Secretary, dated March 12, 2026.

Key Details

• Christopher S. Boerner’s Board membership effective date: March 15, 2026.
• Steven A. Cahillane will not seek reelection at the Annual Meeting on May 8, 2026.
• Boerner’s background: CEO of Bristol‑Myers Squibb since Nov 2023; prior senior roles at Bristol‑Myers Squibb (2015–2023), Seattle Genetics (2010–2015), Genentech (2002–2010), and McKinsey & Company.
• Director compensation: Boerner will be paid as a non‑employee director under Colgate‑Palmolive’s director compensation program described in the company’s March 26, 2025 proxy statement (no new compensation terms disclosed in the 8‑K).

Why It Matters

• This is a governance/board change: a new independent director with deep pharmaceutical and global commercial experience joins the Board, and an existing director (Cahillane) will depart after choosing not to seek reelection.
• The filing does not disclose any immediate financial impact, changes to executive management, or changes to board committees; investors should note the timing ahead of the May 8, 2026 Annual Meeting and review proxy materials for any further governance details.